Novartis and Bristol Myers Squibb moved to pause and investigate CAR-T programs after serious immune complications. Novartis said it is halting and reviewing several clinical trial programs involving rapcabtagene autoleucel (rap-cel) after three patient deaths tied to severe autoimmune inflammatory reactions, including immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). BMS followed by implementing a voluntary pause to review safety data across its zola-cel program after reversible inflammatory events, according to a company spokesperson. Both products target CD19, a key marker on B cells, and both parties cited an abundance of caution while evaluating next steps. Neither company attributed the deaths or events to a confirmed mechanism, and both indicated they intend to resume enrollment as quickly as possible once internal evaluations are complete. The news adds pressure to CAR-T developers to strengthen risk mitigation around cytokine-driven inflammatory toxicities and monitoring pathways. The episode also highlights the continuing scrutiny of autoimmune risk as CAR-T is explored beyond oncology and into autoimmune disease settings.